LifeMD, Inc.
Datakwaliteit: 100%
€ 3,67
▲
€ 0,20
(5,62%)
Marktkapitalisatie: 163,35 M
Prijs
€ 3,41
Marktkapitalisatie
163,35 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—
Quick Summary
Belangrijkste Punten
Revenue grew 20,23% annually over 5 years — strong growth
Generating 6,41 M in free cash flow
P/E of 11,38 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 28,89%
Capital efficient — spends only 0,96% of revenue on capex
Groei
Revenue Growth (5Y)
20,23%
Boven sectorgemiddelde (3,76%)
Revenue (1Y)-8,66%
Earnings (1Y)N/A
FCF Growth (3Y)-13,75%
Kwaliteit
Return on Equity
N/A
ROIC-62,62%
Net Margin7,40%
Op. Margin-3,95%
Veiligheid
Debt / Equity
N/A
Current Ratio0,73
Interest Coverage-5,64
Waardering
PE (TTM|NTM|2027)
11,38 | 7,80 | 7,66
Boven sectorgemiddelde (-1,19)
P/B Ratio124,28
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Services sector mediaan (515 peers)
Sectorvergelijking
vs Services sector mediaan (515 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 11,4 | -1,2 |
| P/B | 124,3 | 1,4 |
| ROE % | — | -16,0 |
| Net Margin % | 7,4 | -19,4 |
| Rev Growth 5Y % | 20,2 | 3,8 |
| D/E | — | 0,4 |
Koersdoel Analisten
8 analisten
Buy
Huidig
€ 3,67
Koersdoel
€ 9,88
€ 8,00
€ 10,00
€ 15,00
Vooruitzicht
Forward K/W
7,80
Forward WPA
€ 0,45
WPA Groei (sch.)
+217,9%
Omzet Sch.
265,23 M
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2027 |
€ 0,45
€ 0,26 – € 0,63
|
265,23 M | 2 |
| FY2026 |
€ 0,14
€ 0,06 – € 0,22
|
223,34 M | 2 |
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| 2026 Q2 |
€ 0,02
€ 0,01 – € 0,02
|
53,87 M | 2 |
| 2026 Q1 |
-€ 0,13
-€ 0,13 – -€ 0,12
|
48,70 M | 2 |
Winstverassingen
Laatste 4 kwartalen
| Kwartaal | Geschat WPA | Werkelijk WPA | Verrassing |
|---|---|---|---|
| Q42025 | € 0,09 | € 0,06 | -36,9% |
| Q32025 | € 0,05 | -€ 0,08 | -285,1% |
| Q22025 | € 0,18 | -€ 0,01 | -106,2% |
| Q12025 | € 0,14 | € 0,03 | -79,9% |
ETFs Holding This Stock
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -8,66% | Revenue Growth (3Y) | 12,79% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 20,23% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 194,06 M | Net Income (TTM) | 14,35 M |
| ROE | N/A | ROA | 20,57% |
| Gross Margin | 85,72% | Operating Margin | -3,95% |
| Net Margin | 7,40% | Free Cash Flow (TTM) | 6,41 M |
| ROIC | -62,62% | FCF Growth (3Y) | -13,75% |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 0,73 |
| Interest Coverage | -5,64 | Asset Turnover | 2,78 |
| Working Capital | -15,58 M | Tangible Book Value | -243.984 |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | 11,38 | Forward P/E | 7,80 |
| P/B Ratio | 124,28 | P/S Ratio | 0,84 |
| PEG Ratio | N/A | Forward PEG | 0,04 |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | 0,62 | Fwd Earnings Yield | 12,82% |
| FCF Yield | 3,92% | ||
| Market Cap | 163,35 M | Enterprise Value | 163,35 M |
| Per Share | |||
| EPS (Diluted TTM) | 0,25 | Revenue / Share | 4,05 |
| FCF / Share | 0,13 | OCF / Share | 0,17 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 0,96% | FCF Conversion | 44,65% |
| SBC-Adj. FCF | -3,83 M | Growth Momentum | -28,89 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 194,06 M | 212,45 M | 152,55 M | 119,03 M | 92,88 M |
| Net Income | 14,35 M | -18,88 M | -20,60 M | -45,54 M | -60,90 M |
| EPS (Diluted) | 0,25 | — | — | — | — |
| Gross Profit | 166,34 M | 188,39 M | 133,65 M | 100,37 M | 74,88 M |
| Operating Income | -7,67 M | -16,14 M | -14,49 M | -43,45 M | -54,30 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | — | — | — | — | — |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | 1,36 M | 2,18 M | 2,60 M | 1,28 M | 3,02 M |
| Income Tax | 45.721,0 | 402.000,0 | 428.000,0 | 360.700,0 | 7.700,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 70,41 M | 72,46 M | 58,48 M | 25,67 M | 49,92 M |
| Total Liabilities | 47,25 M | 76,51 M | 52,91 M | 32,97 M | 24,10 M |
| Shareholders' Equity | 23,16 M | -5,49 M | 3,51 M | -11,40 M | 22,74 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | — | 35,00 M | 33,15 M | 3,96 M | 41,33 M |
| Current Assets | 51,83 M | 48,73 M | 42,60 M | 11,31 M | 44,92 M |
| Current Liabilities | 41,57 M | 60,26 M | 34,78 M | 31,37 M | 22,83 M |
{"event":"ticker_viewed","properties":{"ticker":"LFMD","listing_kind":"stock","pathname":"/stocks/lfmd","exchange":"NASDAQ","country":"US"}}
